The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.r Pulmonary nodulosis

I. Interstitial/parenchymal lung disease

I.ai Acute restrictive lung dysfunction

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

XII. Cardiovascular involvement / toxicity

XII.i Eosinophilic myocarditis

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.w Path: Pulmonary fibrosis (UIP-pattern)

XIX. Pathology

XIX.ck Path: Lymphoproliferative disease, endothoracic

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XXI. Neoplastic conditions

XXI.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.b Eosinophilic pleural effusion

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.f Hiccup

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

XI. Miscellaneous

XI.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.ah Sialorrhea - Drooling

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.i Eosinophilic myocarditis

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

XIX. Pathology

XIX.bu Path: Lymphocytic myocarditis

XIX. Pathology

XIX.cp Path: Eosinophilic myocarditis

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

VI. Pleural and/or pericardial involvement

VI.i Pleuritis (can cause chest pain)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XXVI. Veterinary medicine

XXVI.a Veterinary: Pneumonitis - Interstitial lung disease

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XIII. Esophageal involvement

XIII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

VI. Pleural and/or pericardial involvement

VI.b Eosinophilic pleural effusion

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.h Hypoxemia, low oxygen saturation (may occur in isolation)

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.e Fat/oil embolism - The FES embolism syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.aq Flare of preexisting vasculitis

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XII. Cardiovascular involvement / toxicity

XII.i Eosinophilic myocarditis

XII. Cardiovascular involvement / toxicity

XII.av Aortitis

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.d Alveolar hemorrhage, diffuse (ANCA-positive/-related)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.i Occupational asthma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.f Vocal cord dysfunction, adduction, closure, injury

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.i Pleuritis (can cause chest pain)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.d Pulmonary vasculitis or capillaritis

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.am Dual MPO-/PR3-ANCA systemic disease/vasculitis/pseudovasculitis

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.l Constrictive pericarditis - Pericardial thickening

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.ak Shrinking lung syndrome

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

IV. Airway involvement

IV.ab Cough (lone)

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.x Systemic eosinophilic syndrome w/wo vasculitis (see also Xa)

X. Systemic/Distant conditions, syndromes and reactions

X.al Polyarteritis nodosa-like condition

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.c Pleuritic chest pain

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.au Giant cell myocarditis

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVII. Distinctive patterns - 'Eye-catchers'

XVII.w Eye catcher: Pseudocyanosis

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.ay Path: Pulmonary vasculitis other than capillaritis

XIX. Pathology

XIX.az Path: Granulomatous pulmonary vasculitis

XIX. Pathology

XIX.bb Path: Eosinophilic vasculitis

XIX. Pathology

XIX.ct Path: Brownish macrophages in airspaces (airways - alveoli)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ap Bronchorrhea

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

XVI. Imaging

XVI.g Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.h Path: Pulmonary necrotizing granuloma with neutrophilic microabscesses

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.u Strongyloides stercoralis hyperinfection (w/wo DAH)

XXIII. Rechallenge data

XXIII.b Rechallenge can lead to relapse of AE/ILD